Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
CHICAGO, Oct. 19 /PRNewswire/ -- Seven Summits Strategic Investments releases its Stocks To Watch Guide. The Seven Summits Strategic Investments Stocks To Watch Guide (go to:...
CHICAGO, Oct. 5 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for X, GILD, DOW, BBD, and MVL. Seven Summits Strategic Investments' PriceWatch Alerts are available at...
PRINCETON, N.J., April 28 /PRNewswire/ -- Tickerspy (http://www.tickerspy.com/), an investing website featuring nearly 250 unique, proprietary Indexes, announced the creation of the Swine Flu...
DALLAS, March 12 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today. Investors can view all of the daily trading notes for free by visiting:...
MADISON HEIGHTS, Mich., Jan. 30 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Gildead Sciences, Inc. (NDQ: GILD) as its April...
An all-new interview with Scott Sand, CEO of Ingen Technologies, Inc. is also available on WallSt.net NEW YORK, Feb. 12 /PRNewswire/ -- The Analyst's Review is a daily podcast hosted by...
In the news release, SIRIUS Satellite Named Fastest Growing Company in Deloitte's 2007 Technology Fast 500 Ranking, issued earlier today by Deloitte over PR Newswire, we are advised by the...
Bristol-Myers Squibb and Gilead Sciences Establish U.S. Joint Venture to Develop and Commercialize Fixed-Dose Combination of Three HIV Medicines First Collaboration to Develop a Once-Daily...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
